Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism
- 24 June 2005
- journal article
- clinical trial
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 9 (2) , 142-147
- https://doi.org/10.1007/s10157-005-0342-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patientsKidney International, 2005
- Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2004
- Pathogenesis of refractory secondary hyperparathyroidismKidney International, 2002
- Parathyroid hyperplasia in uremic rats precedes down-regulation of the calcium receptorKidney International, 2001
- History of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy)calcitriol (ED-71)Steroids, 2001
- Medical and surgical aspects of parathyroidectomyKidney International, 1999
- Are we mismanaging calcium and phosphate metabolism in renal failure?American Journal of Kidney Diseases, 1997
- Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidismAmerican Journal of Kidney Diseases, 1996
- Serial Evaluation of Parathyroid Size by Ultrasonography Is Another Useful Marker for the Long-Term Prognosis of Calcitriol Pulse Therapy in Chronic Dialysis PatientsNephron, 1994
- Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolismKidney International, 1993